148 related articles for article (PubMed ID: 17388711)
21. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
Lee JG; Shin BS; Lee YC; Park SW; Kim YH
Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
[TBL] [Abstract][Full Text] [Related]
22. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.
Adler LA; Rotrosen J; Edson R; Lavori P; Lohr J; Hitzemann R; Raisch D; Caligiuri M; Tracy K
Arch Gen Psychiatry; 1999 Sep; 56(9):836-41. PubMed ID: 12892048
[TBL] [Abstract][Full Text] [Related]
23. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
24. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
Goff DC; Renshaw PF; Sarid-Segal O; Dreyfuss DA; Amico ET; Ciraulo DA
Biol Psychiatry; 1993 May; 33(10):700-6. PubMed ID: 8102552
[TBL] [Abstract][Full Text] [Related]
25. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
Wonodi I; Adami H; Sherr J; Avila M; Hong LE; Thaker GK
J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
[TBL] [Abstract][Full Text] [Related]
26. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.
Zhang WF; Tan YL; Zhang XY; Chan RC; Wu HR; Zhou DF
J Clin Psychiatry; 2011 May; 72(5):615-21. PubMed ID: 20868638
[TBL] [Abstract][Full Text] [Related]
27. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H
Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329
[TBL] [Abstract][Full Text] [Related]
28. [Tardive dyskinesia: pergolid, a possible therapeutic option].
Diehl A; Braus DF; Büchel C; Krumm B; Medori R; Gattaz WF
Psychiatr Prax; 2003 Sep; 30(6):333-7. PubMed ID: 12970819
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
Richardson MA; Bevans ML; Read LL; Chao HM; Clelland JD; Suckow RF; Maher TJ; Citrome L
Am J Psychiatry; 2003 Jun; 160(6):1117-24. PubMed ID: 12777270
[TBL] [Abstract][Full Text] [Related]
30. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.
Ghaleiha A; Ghyasvand M; Mohammadi MR; Farokhnia M; Yadegari N; Tabrizi M; Hajiaghaee R; Yekehtaz H; Akhondzadeh S
J Psychopharmacol; 2014 Jul; 28(7):677-85. PubMed ID: 24132248
[TBL] [Abstract][Full Text] [Related]
31. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial.
Loonen AJ; Verwey HA; Roels PR; van Bavel LP; Doorschot CH
J Clin Psychopharmacol; 1992 Feb; 12(1):39-42. PubMed ID: 1348061
[TBL] [Abstract][Full Text] [Related]
32. Vitamin E treatment of tardive dyskinesia.
Adler LA; Peselow E; Rotrosen J; Duncan E; Lee M; Rosenthal M; Angrist B
Am J Psychiatry; 1993 Sep; 150(9):1405-7. PubMed ID: 8102511
[TBL] [Abstract][Full Text] [Related]
33. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
Miller DD; Eudicone JM; Pikalov A; Kim E
J Clin Psychiatry; 2007 Dec; 68(12):1901-6. PubMed ID: 18162021
[TBL] [Abstract][Full Text] [Related]
34. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Woods SW; Saksa JR; Baker CB; Cohen SJ; Tek C
J Clin Psychiatry; 2008 Apr; 69(4):546-54. PubMed ID: 18312060
[TBL] [Abstract][Full Text] [Related]
35. A treatment for tardive dyskinesia and some other extrapyramidal symptoms.
Cowen MA; Green M; Bertollo DN; Abbott K
J Clin Psychopharmacol; 1997 Jun; 17(3):190-3. PubMed ID: 9169964
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I.
van Harten PN; Matroos GE; Hoek HW; Kahn RS
Schizophr Res; 1996 May; 19(2-3):195-203. PubMed ID: 8789918
[TBL] [Abstract][Full Text] [Related]
37. Fluperlapine in tardive dyskinesia and parkinsonism.
Korsgaard S; Noring U; Gerlach J
Psychopharmacology (Berl); 1984; 84(1):76-9. PubMed ID: 6149595
[TBL] [Abstract][Full Text] [Related]
38. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
Lerner V; Kaptsan A; Miodownik C; Kotler M
Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
[TBL] [Abstract][Full Text] [Related]
39. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study.
Shriqui CL; Bradwejn J; Annable L; Jones BD
Am J Psychiatry; 1992 Mar; 149(3):391-3. PubMed ID: 1346951
[TBL] [Abstract][Full Text] [Related]
40. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
